4.7 Article

Novel Helix-Constrained Nociceptin Derivatives Are Potent Agonists and Antagonists of ERK Phosphorylation and Thermal Analgesia in Mice

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 53, 期 23, 页码 8400-8408

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm101139f

关键词

-

资金

  1. Australian Research Council (ARC) [DP0210330, DP0770936, DP1093245, FF668733]
  2. National Health and Medical Research Council [511194]
  3. Ministerio de Educacion y Ciencia (MEC)
  4. Fundacion Espanola para la Ciencia y la Tecnologia (FECYT) (Spain)
  5. Australian Research Council [DP0770936, DP0210330] Funding Source: Australian Research Council

向作者/读者索取更多资源

The nociceptin opioid peptide receptor (NOP, NOR, ORL-1) is a GPCR that recognizes nociceptin, a 17-residue peptide hormone. Nociceptin regulates pain transmission, learning, memory, anxiety, locomotion, cardiovascular and respiratory stress, food intake, and immunity. Nociceptin was constrained using an optimized helix-inducing cyclization strategy to produce the most potent NOP agonist (EC50=40 pM) and antagonist (IC50=7.5 nM) known. Alpha helical structures were measured in water by CD and 2D H-1 NMR spectroscopy. Agonist and antagonist potencies, evaluated by ERK phosphorylation in mouse neuroblastoma cells natively expressing NOR, increased 20-fold and 5-fold, respectively, over nociceptin. Helix-constrained peptides with key amino acid substitutions had much higher in vitro activity, serum stability, and thermal analgesic activity in mice, without cytotoxicity. The most potent agonist increased hot plate contact time from seconds up to 60 min; the antagonist prevented this effect. Such helix-constrained peptides may be valuable physiological probes and therapeutics for treating some forms of pain.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据